The US Food and Drug Administration (FDA) yesterday announced it has approved Merck’s Ebola vaccine, a key development that brings a licensed vaccine to the market for public health preparedness.
In other Ebola developments, two new cases were reported in the Democratic Republic of the Congo (DRC) outbreak, as the World Health Organization (WHO) noted that young children in the affected areas aren’t as likely to be referred to Ebola treatment centers as their older peers are.
FDA announcement caps 6-month review
Photo credit: (CC BY 2.0), Flickr, NIAID
The post FDA approves Merck Ebola vaccine amid more DRC cases appeared first on Healthier Environment Living Program.